Determining the accuracy of next generation sequencing based copy number variation analysis in Hereditary Breast and Ovarian Cancer

Expert Rev Mol Diagn. 2022 Feb;22(2):239-246. doi: 10.1080/14737159.2022.2048373. Epub 2022 Mar 10.

Abstract

Background: Copy number variations (CNVs) are commonly associated with malignancies, including hereditary breast and ovarian cancers. Next generation sequencing (NGS) provides solutions for CNV detection in a single run. This study aimed to compare the accuracy of CNV detection by NGS analyzing tool against Multiplex Ligation Dependent Probe Amplification (MLPA).

Research design and methods: In total, 1276 cases were studied by targeted NGS panels and 691 cases (61 calls in 58 NGS-CNV positive and 633 NGS-CNV negative cases) were validated by MLPA.

Results: Twenty-eight (46%) NGS-CNV positive calls were consistent, whereas 33 (54%) calls showed discordance with MLPA. Two cases were detected as SNV by the NGS and CNV by the MLPA analysis. In total, 2% of the cases showed an MLPA confirmed CNV region in BRCA1/2. The results of this study showed that despite the high false positive call rate of the NGS-CNV algorithm, there were no false negative calls. The cases that were determined to be negative by the NGS and positive by the MLPA were actually carrying SNVs that were located on the MLPA probe binding sites.

Conclusion: The diagnostic performance of NGS-CNV analysis is promising; however, the need for confirmation by different methods remains.

Keywords: BRCA1; BRCA2; Next generation sequencing; copy number variation; multiplex ligation dependent amplification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Ovarian Epithelial
  • DNA Copy Number Variations*
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Multiplex Polymerase Chain Reaction / methods
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / genetics